Tourmaline Bio (NASDAQ:TRML - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.05, Zacks reports.
Tourmaline Bio Price Performance
Shares of Tourmaline Bio stock opened at $16.27 on Thursday. The stock has a market capitalization of $417.21 million, a PE ratio of -5.77 and a beta of 2.35. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $48.31. The company's fifty day simple moving average is $15.83 and its 200-day simple moving average is $20.84.
Wall Street Analyst Weigh In
Several analysts recently commented on TRML shares. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Wedbush assumed coverage on Tourmaline Bio in a research report on Thursday, March 6th. They issued an "outperform" rating and a $42.00 price objective on the stock. BMO Capital Markets began coverage on Tourmaline Bio in a report on Friday, December 6th. They issued an "outperform" rating and a $50.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $49.00 price target on shares of Tourmaline Bio in a report on Wednesday, December 11th. Finally, Guggenheim reiterated a "buy" rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tourmaline Bio presently has an average rating of "Buy" and an average price target of $52.86.
Get Our Latest Stock Report on Tourmaline Bio
About Tourmaline Bio
(
Get Free Report)
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tourmaline Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.
While Tourmaline Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
